ID
24655
Beskrivning
Study part: Non- Serious Adverse Event (AE). A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Clinicaltrials.gov Identifier: NCT00355641. Phase: phase 3. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP, Zygara; Zygara, ZIPEREVE, ZEPREVE, Requip Depot, REQUIP, REPREVE, Modutab, ADARTREL. Study Indication : Restless Legs Syndrome. Study ID: 101468/206. Clinical Study ID: 101468/206.
Nyckelord
Versioner (1)
- 2017-08-11 2017-08-11 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
11 augusti 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Non- Serious Adverse Event (AE) Ropinirole Restless Legs Syndrom NCT00355641
Non- Serious Adverse Event (AE)
- StudyEvent: ODM
Similar models
Non- Serious Adverse Event (AE)
- StudyEvent: ODM
C1518404 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,2])
C2826793 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])
C1762893 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])